Natural product-derived therapy for Human Leukemias: Eriocitrin, found in lemons, suppresses B-Cell and myeloid leukemias via up regulation of the tumor suppressor IRF4, 10/December/2016, 11.56 pm
Introduction: What they say: Noble laureate in Physiology/Medicine (1975) Prof. David Baltimore, from California Institute of Technology, California, USA, had reported in the July 8, 2014 issue of the Journal “Blood” that: “Dual mechanisms by which MiR-125b represses IRF4 to induce myeloid/B-cell leukemias.” What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-derived therapy for Human Leukemias: […]
Natural product-derived therapy for Human Leukemias: Ganoderma lucidum suppresses B-Cell and myeloid leukemias via up regulation of the tumor suppressor IRF4, 10/December/2014, 11.48 pm
Introduction: What they say: Noble laureate in Physiology/Medicine (1975) Prof. David Baltimore, from California Institute of Technology, California, USA, had reported in the July 8, 2014 issue of the Journal “Blood” that: “Dual mechanisms by which MiR-125b represses IRF4 to induce myeloid/B-cell leukemias.” What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-derived therapy for Human Leukemias: […]
Therapeutic insights into “awakening the sleeping/cancer-protecting angels” in mutant p53-expressing human tumors: MyoD increases the expression of tumor suppressor p53 homologue TA-p73/p63, PTEN, TPM1, TIMP3, BTG2, PDCD4, SPRY1/2 and CCM1/KRIT1 and induces regression of p53-mutated human tumors via down regulation of its target gene, 10/December/2016, 11.18 pm
From Significance of the study to Public health relevance: Given that: (1) Cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53 pathway is altered in about 80% of tumors.; (3) our understanding is incomplete in terms of molecular targets and the oncogenic/malignant pathways involved in mutant […]
Natural product-derived Lifespan extension therapy: Persimmon tannin fruit extract increases life span via up-regulation of its target gene BubR1, 10/December/2016, 7.41 pm
What they say: Introduction: A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published in the 1 July 2014 issue of the journal “EMBO” by Prof […]
Natural product-derived therapy for triple-negative breast tumors: Cucurbitacin D, found in Trichosanthes kirilowii (Gualou), Phormium tenax, and Luffa amara among others, increases the levels of cell cycle inhibitor, p27, inhibits pro-survival pathways mediated by c-Myc, and inhibits the progression of triple-negative breast cancer via up-regulation of its target gene, 10/December/2016, 7.21 pm
Introduction: What they say A study from the Department of Cell and Tissue Biology, University of California, San Francisco (UCSF), San Francisco, California, USA shows that “PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression” Another study, carried out in parallel, from the Breast Cancer Now Research Unit, Division […]
Natural product-derived PD-1 pathway blockade for Human cancer therapy: Moringa Olifera extract decreases the expression of Glycogen synthase kinase-3β, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene, 10/December/2016, 6.34 pm
Introduction:What they say: A recent study from Cell Signalling Section, Division of Immunology, Department of Pathology, Tennis Court Road, University of Cambridge, Cambridge CB2 1QP, UK shows that “Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8(+) Cytolytic T Cell Responses.” This study was published in the 16 February 2016 issue […]
